Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer.

Kaufman, Peter A; Neuberger, Edward; Schwartz, Naomi R M; Wang, Shu; Liu, Yutong; Hsu, Ling-I; Bartley, Karen; Blahna, Matthew T; Pittner, Brian T; Wong, Gabriel; Anders, Carey

Kaufman, Peter A; Neuberger, Edward; Schwartz, Naomi R M; Wang, Shu; Liu, Yutong; Hsu, Ling-I; Bartley, Karen; Blahna, Matthew T; Pittner, Brian T; Wong, Gabriel; Anders, Carey.

Afiliação

Kaufman PA; Division of Hematology and Oncology, University of Vermont Medical Center, Burlington, VT, United States.
Neuberger E; Seagen Inc., Bothell, WA, United States.
Schwartz NRM; Seagen Inc., Bothell, WA, United States.
Wang S; Genesis Research, Hoboken, NJ, United States.
Liu Y; Genesis Research, Hoboken, NJ, United States.
Hsu LI; Seagen Inc., Bothell, WA, United States.
Bartley K; Seagen Inc., Bothell, WA, United States.
Blahna MT; Seagen Inc., Bothell, WA, United States.
Pittner BT; Seagen Inc., Bothell, WA, United States.
Wong G; Seagen Inc., Bothell, WA, United States.
Anders C; Division of Medical Oncology, Duke Cancer Institute, Durham, NC, United States.

Front Oncol ; 13: 1264861, 2023.

Article em En | MEDLINE | ID: mdl-37849811

Palavras-chave

HER2+; brain metastases; metastatic breast cancer; real-world; tucatinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google